Natco Pharma gets USFDA’s EIR for Visakhapatnam plant

August inspection drew four Form-483 observations; regulator classifies as Voluntary Action Indicated
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Natco Pharma (NATCOPHARM).
- Category: Company.
Why it matters
A routine update for Natco Pharma. Use the price and stock snapshot to gauge how the market is responding.









